top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

David Meeker Biography and Net Worth

CEO of Rhythm Pharmaceuticals

Dr. David Meeker, a member of Rhythm’s Board of Directors since 2015 and Chairman of the Board since 2017, was appointed President and Chief Executive Officer of the Company in July 2020. Most recently, he served as President and CEO of KSQ Therapeutics for approximately three years. Previously, David was the Executive Vice President and Head of Sanofi Genzyme, the specialty-care global business unit of Sanofi that focused on rare diseases, multiple sclerosis, oncology and immunology. He joined Genzyme in 1994 as Medical Director and, over the course of his tenure, served the company as Vice President of Medical Affairs, Chief Operating Officer, and Chief Executive Officer. He led Genzyme’s commercial organization and global market access functions and managed the launch of several treatments for rare genetic diseases, including Aldurazyme®, Fabrazyme® and Myozyme®. Prior to his tenure with Genzyme, David was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker earned his M.D. from the University of Vermont Medical School and completed the advanced management program at Harvard Business School.

What is David P. Meeker's net worth?: The estimated net worth of David P. Meeker is at least $17.28 million as of August 27th, 2024. Dr. Meeker owns 352,489 shares of Rhythm Pharmaceuticals stock worth more than $17,279,011 as of October 24th. This net worth estimate does not reflect any other assets that Dr. Meeker may own. Additionally, Dr. Meeker receives a salary of $1,350,000.00 as CEO at Rhythm Pharmaceuticals. Learn More about David P. Meeker's net worth.
How old is David P. Meeker?: Dr. Meeker is currently 70 years old. There are 6 older executives and no younger executives at Rhythm Pharmaceuticals. Learn More on David P. Meeker's age.
What is David P. Meeker's salary?: As the CEO of Rhythm Pharmaceuticals, Inc., Dr. Meeker earns $1,350,000.00 per year. Learn More on David P. Meeker's salary.
How do I contact David P. Meeker?: The corporate mailing address for Dr. Meeker and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at [email protected]. Learn More on David P. Meeker's contact information.
Has David P. Meeker been buying or selling shares of Rhythm Pharmaceuticals?: David P. Meeker has not been actively trading shares of Rhythm Pharmaceuticals during the last ninety days. Most recently, David P. Meeker sold 45,494 shares of the business's stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $39.22, for a transaction totalling $1,784,274.68. Following the completion of the sale, the chief executive officer now directly owns 174,605 shares of the company's stock, valued at $6,848,008.10. Learn More on David P. Meeker's trading history.
Who are Rhythm Pharmaceuticals' active insiders?: Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Jennifer Good (Director), Jennifer Lee (EVP), Yann Mazabraud (EVP), David Meeker (CEO), Joseph Shulman (Insider), Hunter Smith (CFO), and Lynn Tetrault (Director). Learn More on Rhythm Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rhythm Pharmaceuticals?: In the last twelve months, insiders at the sold shares 25 times. They sold a total of 331,893 shares worth more than $15,042,769.51. The most recent insider tranaction occured on September, 17th when Director Jennifer L Good sold 31,751 shares worth more than $1,663,752.40. Insiders at Rhythm Pharmaceuticals own 5.6% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.
Information on this page was last updated on 9/17/2024.

David P. Meeker Insider Trading History at Rhythm Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2024	Sell	45,494	$39.22	$1,784,274.68	174,605
3/30/2021	Buy	10,000	$20.17	$201,700.00	111,335
10/10/2017	Buy	25,000	$17.00	$425,000.00

David P. Meeker Buying and Selling Activity at Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $49.02

$48.17

$49.63

50 Day Range

MA: $49.24

$44.19

$54.55

2 Week Range

Now: $49.02

$21.34

$55.64

Volume

387,359 shs

Average Volume

533,367 shs

Market Capitalization

$3.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

24/7 Automated Profits in Crypto

From Crypto Swap Profits | Ad

The 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.

David Meeker Biography and Net Worth

What is David P. Meeker's net worth?

How old is David P. Meeker?

What is David P. Meeker's salary?

How do I contact David P. Meeker?

Has David P. Meeker been buying or selling shares of Rhythm Pharmaceuticals?

Who are Rhythm Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Rhythm Pharmaceuticals?